EGFR and non-small cell lung carcinoma: The TRAEMOS phase I/II study (NCT03784599) is investigating the combination of osimertinib and trastuzumab–emtansine, a conjugate of the mAb trastuzumab and the cytotoxic agent DM1, which was reported to overcome osimertinib resistance in T790M-positive EGFR-mutated NSCLC cell lines that gained HER2 amplification.73